Search
forLearn
5 / 801 resultslearn riboflavin
learn Procyanidin B-2
learn Ceramide A2
learn RH410
Research
5 / 1000+ results
research Telogen Effluvium due to Recombinant Interferon α-2b
Half of the patients treated with a specific drug for skin cancer experienced hair loss not related to the drug's dosage.
research INTERFERONS IN DERMATOLOGY
Interferons are effective for some skin conditions and cancers, but can have side effects and need more research for optimal use.
research Regulation of pathophysiological and tissue regenerative functions of MSCs mediated via the WNT signaling pathway (Review)
The WNT signaling pathway is crucial for mesenchymal stem cells' function and therapy success.
research A Hot New Twist to Hair Biology
Capsaicin, found in chili peppers, can slow down hair growth by affecting skin cells and hair follicles.
research Interferon in the treatment of cutaneous T-cell lymphoma
Interferon, especially alfa interferon, is an effective treatment for cutaneous T-cell lymphoma with manageable side effects.
Community Join
5 / 1000+ resultscommunity ru58841 in europe, without getting water in the mail.
The conversation is about finding a trustworthy and affordable source for RU58841 in Europe, with a comparison between Anagenic and Actifolic. The user seeks experiences from others in the EU to avoid receiving water instead of the product.
community Eirion ET-02( RS 5441) managed to defeat rodents, finally
ET-02 (RS 5441) shows promising results for hair growth, performing better in humans than in mice. There is debate over the effectiveness compared to minoxidil, with some users wanting more detailed data.
community ICYMI: Eirion ET-02’s Successful Phase 1 Trial Results for Androgenic Alopecia Treatment
ET-02 showed significant hair growth in five weeks, outperforming minoxidil, with a non-hormonal mechanism that avoids side effects of treatments like finasteride. A phase 2 trial is planned to further assess ET-02's efficacy and safety.
community Trial for TDM-105795 update from research office
The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.
community AH-001 another topical AR degrader beside GT20029, completed Phase I
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.